Position
Fidelity in ARS Pharmaceuticals, Inc.
Back to the book · All holders of SPRY
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$6.84K$8.03 → $8.01
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 399K | $4.65M | — | — | — | 0.0% |
| Q1 2026 | 342K | $2.75M | $8.03 | −$1.24M | −$663.1K | 0.0% |
| Q2 2026 | 349.2K | $2.8M | $8.01 | −$6.84K | $57K | 0.0% |